

# Stanley Shaldon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10986930/publications.pdf>

Version: 2024-02-01

26  
papers

1,223  
citations

687363

13  
h-index

677142

22  
g-index

28  
all docs

28  
docs citations

28  
times ranked

331  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling â€“ Guest Editors: Stanley Shaldon and Joerg Vienken: An Introduction. Seminars in Dialysis, 2009, 22, 252-252.	1.3	2
2	Beyond The Current Paradigm: Recent Advances in The Understanding of Sodium Handling â€“ Guest Editors: Stanley Shaldon and Joerg Vienken: Salt, the Neglected Silent Killer. Seminars in Dialysis, 2009, 22, 264-266.	1.3	15
3	From Isolated Ultrafiltration to Blood-Temperature-Controlled Feedback: An Odyssey Started by Jonas BergstrÃ¶m. Blood Purification, 2006, 24, 218-221.	1.8	5
4	Opinion: What Clinical Insights from the Early Days of Dialysis Are Being Overlooked Today?. Seminars in Dialysis, 2005, 18, 18-19.	1.3	4
5	Monitoring of unattended overnight hemodialysis in the home. Hemodialysis International, 2005, 9, 68-69.	0.9	1
6	Salt restriction and not length of dialysis is the key to drug free blood pressure control in ESRD patients. Journal of Nephrology, 2003, 16, 159.	2.0	3
7	Recombinant versus natural human <sup>111</sup> In- <sup>125</sup> I-microglobulin for scintigraphic detection of <sup>125</sup> I amyloid in dialysis patients. Kidney International, 2000, 58, 873-880.	5.2	17
8	Biocompatibility â€“ Clinical Aspects. , 1996, , 734-749.		1
9	Impaired endotoxin-induced interleukin-1 $\beta$ secretion, not total production, of mononuclear cells from ESRD patients. Kidney International, 1995, 47, 1158-1167.	5.2	18
10	Biocompatibility in Hemodialysis: Clinical Relevance in 1995. Artificial Organs, 1995, 19, 395-397.	1.9	5
11	Gene expression of interleukin-1 $\beta$ during hemodialysis. Kidney International, 1993, 43, 712-721.	5.2	105
12	Permeability of dialyzer membranes to TNF $\alpha$ -inducing substances derived from water bacteria. Kidney International, 1992, 42, 61-68.	5.2	144
13	Should Cuprophane Membranes Continue to Be Used for Chronic Hemodialysis?. Seminars in Dialysis, 1992, 5, 112-113.	1.3	0
14	Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney International, 1990, 37, 85-93.	5.2	187
15	Imaging of dialysis-related amyloid (AB-amyloid) deposits with <sup>131</sup> I- <sup>125</sup> I-microglobulin. Kidney International, 1990, 38, 1169-1176.	5.2	54
16	The Interleukin Hypothesis: A Reappraisal after 6 Years. Seminars in Dialysis, 1989, 2, 172-175.	1.3	7
17	Detection of endotoxin-like interleukin-1-inducing activity during in vitro dialysis. Kidney International, 1988, 33, 29-35.	5.2	138
18	Plasma Interleukin-1 Activity during Hemodialysis: The Influence of Dialysis Membranes. Nephron, 1988, 50, 273-276.	1.8	68

#	ARTICLE	IF	CITATIONS
19	The interleukin hypothesis. Journal of Japanese Society for Dialysis Therapy, 1988, 21, 1085-1089.	0.0	0
20	Biological Consequences of Monocyte Activation during Hemodialysis. Contributions To Nephrology, 1987, 59, 1-9.	1.1	9
21	Haemodialysis Monitors and Monitoring. , 1983, , 223-241.		8
22	Hemodynamic changes during sequential ultrafiltration and dialysis. Kidney International, 1979, 15, 411-418.	5.2	91
23	Use of Internal Arteriovenous Fistula in Home Haemodialysis. BMJ: British Medical Journal, 1968, 4, 671-673.	2.3	33
24	Portal hypertension in the myeloproliferative syndrome and the reticuloses. American Journal of Medicine, 1962, 32, 758-764.	1.5	116
25	Effect of Pitressin on the Splanchnic Circulation in Man. Circulation, 1961, 24, 797-807.	1.6	79
26	THE USE OF VASOPRESSIN ('PITRESSIN') IN THE CONTROL OF BLEEDING FROM Å'SOPHAGEAL VARICES. Lancet, The, 1960, 276, 222-225.	13.7	109